Navigation Links
Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System
Date:6/26/2008

PRINCETON, N.J., June 26 /PRNewswire/ -- Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has resumed European clinical activities on its TOPS(TM) System, a Total Posterior Arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis. The procedure was performed by the Lead Clinician of the London Spine Clinic, Mr. John C. Sutcliffe, MB ChB, FRCS.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO )

Impliant had voluntarily suspended all clinical activities in September of last year following one device-related failure. After an extensive investigation conducted by a third-party expert in medical device retrievals and the Impliant Research and Development team, it was determined that device misalignment coupled with excessive shear loading caused the failure. As a result, Impliant has made a few minor design and manufacturing changes to the internal components of the TOPS(TM) device that allow it to better withstand high shear loads and misalignment while not affecting its range of motion.

"I am pleased with the changes Impliant has made to the TOPS(TM) System," said Mr. Sutcliffe. "I feel the device is now even better suited to stabilize the spinal segment after performing the wide decompression that my severely stenotic patients require. However, it should be noted that all of my patients with the original TOPS(TM) design continue to do extremely well, some of which have reached 12 months post-op."

Marcus Klarl, Vice President of European Clinical Affairs for Impliant, stated, "We are pleased to resume our TOPS(TM) clinical activities outside the United States and build upon the excellent outcomes generated to date by Mr. Sutcliffe and our other TOPS(TM) investigators."

The TOPS(TM) single and multi-level family of products have been implanted in over 80 patients in Brazil, South Africa, Belgium, Turkey, Israel, Germany and the United Kingdom. The company also recently received FDA approval to restart its TOPS(TM) IDE clinical study in the United States.

Impliant is applying cutting-edge materials and crossbar biomechanical techniques to develop a new class of spine arthroplasty devices that target over 40% of the patients worldwide who undergo fusion surgery and could benefit from a Total Posterior Arthroplasty solution.

About the TOPS(TM) System

Impliant's TOPS(TM) System, a mobile posterior device, is designed to stabilize but not fuse the L3-4 or L4-5 vertebral level to alleviate pain stemming from spinal stenosis with or without degenerative facet arthrosis and spondylolisthesis. Following a laminectomy and medial facetectomy, the device is affixed to the spine via four pedicle screws using a standard posterior surgical approach. Impliant believes that the TOPS(TM) System could benefit over 500,000 patients worldwide undergoing spinal fusion surgery each year. Impliant obtained CE Mark approval for the TOPS(TM) System on June 1, 2006.

About Impliant, Inc.

Impliant, Inc. is a privately held company engaged in the development of novel spine arthroplasty solutions for some of the most prevalent pathologies of the spine. The company is currently developing the TOPS(TM) System, which has the longest clinical history in the Total Posterior Arthroplasty market segment, dating to January 2005. Impliant is also developing several next- generation and multi-level technologies to further increase its addressable market. Impliant is headquartered in Princeton, NJ with research facilities located in Ramat Poleg, Israel. Shareholders include Elron Electronic Industries Ltd. (Nasdaq, TASE: ELRN). For more information about Impliant, please visit http://www.impliant.com.


'/>"/>
SOURCE Impliant, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. Launch of second European Cancer Research Funding survey
7. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
8. Pharsight to Host European Software Conference
9. OmniGuide Begins European Commercialization
10. Paving the way for future pan-European clinical trials
11. US, European cancer educators gather in Alabama for meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm ... 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Workrite Ergonomics, ... company that has evolved from humble beginnings to being an internationally recognized leader in ... that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the ...
(Date:2/10/2016)... ... 2016 , ... Anxiety of older Americans over steep cost increases of prescription ... decade ago, according to The Senior Citizens League (TSCL). Since last ... with rapidly rising costs. “The implications are chilling, particularly for people with chronic ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 09, 2016 , ... ... surgeons are witnessing a dramatic increase in the number of patients under the age ... reflects what they are seeing in their offices, and may indicate an overall shift ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... ALSP, Inc. announced that it has appointed Col.(Retired) ... Affairs in preparation for its move into clinical trials with ... stated, "We are pleased to welcome Dallas Hack ... an individual of such practical knowledge and far-reaching experience in ... on his broad experience and success as a clinician and ...
(Date:2/10/2016)... 2016 Intouch Solutions, a leading marketing agency ... trend regarding the evolution of digital sales aids ... deliver compelling sales presentations via tablets. After conducting ... 2015, Intouch uncovered that while most pharmaceutical representatives ... many are not using them effectively during physician ...
(Date:2/10/2016)... -- Until recently, the options for reducing the appearance of ... approved the non-invasive Coolsculpting treatment, which removes fat cells ... in 2010 for the abdomen and this approval was ... this add-on approval, the experts at Laser Therapy Health ... CoolMini, to address smaller areas of fat. ...
Breaking Medicine Technology: